Core Viewpoint - The company has successfully passed the consistency evaluation for the generic drug Roxithromycin capsules (150mg) through the National Medical Products Administration of China, reinforcing its competitive position in the anti-infection sector [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has received approval for Roxithromycin capsules, marking it as the first enterprise to pass the consistency evaluation for this formulation [1] - Roxithromycin is a second-generation macrolide antibiotic known for its acid resistance, broad antibacterial spectrum, strong tissue penetration, and low incidence of adverse reactions [1] Group 2: Clinical Applications - Roxithromycin capsules are clinically applicable for treating infections caused by Roxithromycin-sensitive pathogens, including those affecting the ear, nose, throat, respiratory tract, skin, soft tissues, and urogenital tract [1] Group 3: Market Position and Future Outlook - The product is listed as a Class B drug in the National Medical Insurance Directory (2025 version), which is expected to enhance the company's market position in the anti-infection field [1] - The company aims to continue its commitment to new product development, anticipating greater returns for itself and its shareholders [1]
联邦制药：罗红霉素胶囊通过一致性评价